AU2021285273A1 - Methods of treatment of tuberous sclerosis complex - Google Patents

Methods of treatment of tuberous sclerosis complex Download PDF

Info

Publication number
AU2021285273A1
AU2021285273A1 AU2021285273A AU2021285273A AU2021285273A1 AU 2021285273 A1 AU2021285273 A1 AU 2021285273A1 AU 2021285273 A AU2021285273 A AU 2021285273A AU 2021285273 A AU2021285273 A AU 2021285273A AU 2021285273 A1 AU2021285273 A1 AU 2021285273A1
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021285273A
Other languages
English (en)
Inventor
George GARIBALDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noema Pharma AG
Original Assignee
Noema Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma AG filed Critical Noema Pharma AG
Publication of AU2021285273A1 publication Critical patent/AU2021285273A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
AU2021285273A 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex Pending AU2021285273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
US63/035,313 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
AU2021285273A1 true AU2021285273A1 (en) 2023-01-19

Family

ID=76325558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021285273A Pending AU2021285273A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Country Status (13)

Country Link
US (3) US11684613B2 (https=)
EP (1) EP4161512A1 (https=)
JP (2) JP2023528895A (https=)
KR (2) KR20230027145A (https=)
CN (1) CN116056701A (https=)
AU (1) AU2021285273A1 (https=)
BR (1) BR112022024760A2 (https=)
CA (1) CA3180794A1 (https=)
CL (1) CL2022003435A1 (https=)
IL (2) IL322310A (https=)
MX (1) MX2022015407A (https=)
PH (1) PH12023550016A1 (https=)
WO (1) WO2021245281A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa
EP4658268A1 (en) * 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa

Also Published As

Publication number Publication date
CA3180794A1 (en) 2021-12-09
IL298709A (en) 2023-02-01
US20230100520A1 (en) 2023-03-30
CN116056701A (zh) 2023-05-02
JP2025122066A (ja) 2025-08-20
PH12023550016A1 (en) 2024-03-11
US20230277513A1 (en) 2023-09-07
US11998535B2 (en) 2024-06-04
JP2023528895A (ja) 2023-07-06
BR112022024760A2 (pt) 2023-03-07
KR20250116184A (ko) 2025-07-31
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27
IL322310A (en) 2025-09-01
EP4161512A1 (en) 2023-04-12
MX2022015407A (es) 2023-05-16
WO2021245281A1 (en) 2021-12-09
CL2022003435A1 (es) 2023-10-20
KR20230027145A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
US20250099445A1 (en) Methods of treatment of tuberous sclerosis complex
EP2168585B1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
EA029180B1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
WO2021245280A9 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
US20250345320A1 (en) Methods of treatment of trigeminal neuralgia
CN109721557B (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
WO2024118936A1 (en) 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies
OA21124A (en) Methods of treatment of trigeminal neuralgia.
WO2025096684A1 (en) Err modulators
HK1140947B (en) Pharmaceuticals compositions of a neuroactive steroid and uses thereof
HK1145987A (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
HK1118202B (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof